Oncology companies develop therapies, diagnostics and technologies that support the detection, monitoring and treatment of cancer. The sector is one of the largest and most active areas of biotechnology and pharmaceutical innovation.
This category includes companies working on:
Browse 291 UK oncology companies below.
Gene therapy immune regulators for infection, cancer and autoimmunity
Virothera develops gene therapies intended to regulate immune responses in persistent diseases. Its approach draws on human versions of immune-modifying proteins that viruses have evolved to influence immune cells. The company aims to use these proteins to create targeted treatments with potential advantages over some…
Specialty biopharma covering oncology, neurology, and fertility
Merck Serono Limited is the UK commercial subsidiary of Merck KGaA's Healthcare division, a German science and technology company founded in 1668. The UK operation markets prescription medicines across oncology, neurology, immunology, endocrinology, and fertility. Key products include Erbitux for colorectal and…
Clinical-stage oncology biopharma developing the bispecific antibody ivonescimab
Summit Therapeutics is a clinical-stage oncology company with UK research operations originating from VASTox, a University of Oxford spin-out. The company's lead candidate, ivonescimab, is a bispecific antibody targeting PD-1 and VEGF, in-licensed from Akeso and now in multiple global Phase III trials across non-small…
Immuno-oncology target discovery and antibody therapeutics developer
4C Biomed is a biotechnology company developing immuno-oncology therapies and target discovery platforms based on patient-derived tumour and immune cell systems. The company uses integrated screening technologies and clinical data to identify novel immune targets and develop antibody therapeutics designed to enhance…
RNA immunotherapies targeting novel tumour-specific antigens
Epitopea is a biopharma company developing off-the-shelf RNA-based immunotherapies for hard-to-treat cancers. Using spatial immunopeptidomics, genomics, and systems bioinformatics, the company identifies aberrantly-expressed tumour-specific antigens that are broadly shared across patients with the same tumour type.…
Clinical-stage biopharma developing treatments for cancer and rare diseases
Biodexa Pharmaceuticals is a Cardiff-based clinical-stage biopharmaceutical company advancing a pipeline of proprietary drug formulations for diseases with high unmet need. Its lead programme, eRapa, an encapsulated oral formulation of rapamycin, is in a Phase 3 registrational trial for familial adenomatous polyposis,…
Non-viral intracellular drug delivery for solid tumours
Vitarka Therapeutics is a preclinical biotech company developing a non-viral drug delivery platform for targeted intracellular delivery of therapeutics to solid tumours. The technology uses pore-forming proteins to transport RNAi therapies and other payloads directly into cancer cells while limiting off-target…
Genome-editing platform mapping cancer drug resistance and druggable vulnerabilities
BASE Rx is a Wellcome Sanger Institute spin-out applying genome-editing and DNA sequencing technologies to cancer drug discovery. The company maps single-base genetic variants to identify druggable vulnerabilities in cancer genes and predict the DNA changes that drive resistance to cancer therapies. BASE Rx aims to…
AI drug discovery platform developing novel biologics for cancer and AMR
AMPLY Discovery is a biotechnology company developing an AI-driven drug discovery platform that combines machine learning, next-generation sequencing, and synthetic biology to identify novel biologic drug candidates from natural biological diversity. The platform digitises biological molecules, identifies treatment…
Small activating RNA therapeutics for gene upregulation and disease
MiNA Therapeutics is a clinical-stage biotechnology company pioneering small activating RNA medicines, a class of oligonucleotide therapeutics that restore or boost expression of underactive genes by activating transcription rather than silencing it. The approach targets diseases driven by loss of normal gene…
Synthetic glycan-targeted small molecules for next-generation immunotherapy
Anomer Bio is a biotechnology company developing synthetic monosaccharides and small molecule drugs that target glycans, the sugars coating cell surfaces that influence immune responses and disease. Its platform combines multi-omics data and machine learning to model how cells process sugars, enabling the design of…
Cocrystal drug repurposing for oncology supportive care and fibrosis
Nuformix is a pharmaceutical development company using proprietary cocrystal technology to repurpose existing drugs for unmet medical needs in fibrosis and oncology. By reengineering a drug's crystal form, the company improves properties such as dissolution and absorption, creating differentiated, patentable products…
Preclinical in vitro bioassay CRO for drug discovery programmes
Cellomatics Biosciences is a UK-based contract research organisation providing bespoke preclinical in vitro bioassay services to biotechnology and pharmaceutical clients. The company specialises in cell-based assays, phenotypic screening, target validation, and toxicity profiling across oncology, immuno-oncology,…
Organ-specific liquid biopsy tests for early cancer detection
Mursla Bio is a diagnostics company developing blood-based tests for early cancer detection using extracellular vesicle biology. Its platform isolates organ-specific extracellular vesicles from blood and applies multi-omics profiling and machine learning to identify disease biomarkers without tissue biopsy. Its lead…
Targeted oral drug delivery platform for cancer, CNS and respiratory disease
TRX Biosciences is a biotechnology company developing a targeted oral drug delivery platform, enabling therapies to reach specific organs, cells and tissues for cancer, central nervous system, respiratory and immune system diseases. The company's technology is licensed to partner companies for use in their own drug…
Targeted therapies against extrachromosomal DNA in cancer
Econic Biosciences is a drug discovery biotech developing therapies that target extrachromosomal DNA, a circular form of DNA found outside normal chromosomes that drives oncogene amplification, tumour evolution, and treatment resistance across multiple cancer types. The company uses AI to identify and characterise…
Bispecific antibody-drug conjugates for hard-to-treat solid tumours
Valink Therapeutics is a biotechnology company developing next-generation bispecific antibody-drug conjugates and multispecific antibody therapeutics for oncology. Its proprietary discovery platform enables modular assembly of complex antibody formats combining multispecificity, multivalency, and drug conjugation,…
PET radiopharmaceutical diagnostics for cancer imaging
Blue Earth Diagnostics Limited is a molecular imaging company developing and commercialising PET radiopharmaceuticals for cancer diagnosis and treatment planning. The company serves clinicians, healthcare systems and patients by providing administered imaging agents that support clinical decision making in oncology.…
Global pharma company in oncology, immunology, and neuroscience
Johnson & Johnson is a multinational pharmaceutical company with UK operations spanning commercial, medical affairs, and innovation activities. Its Innovative Medicine division covers oncology, immunology, neuroscience, and infectious disease. The company operates an EMEA Innovation Centre in London focused on…
Diverse oncology datasets for AI-driven precision medicine research
CureCollect is a life science data company sourcing multimodal oncology datasets for precision medicine and artificial intelligence research. It collaborates with hospitals and laboratories to assemble pathology images, genomic and transcriptomic data, longitudinal clinical records and treatment outcomes from diverse…